Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Effectiveness of Denosumab Therapy after Treatment with Bisphosphonates in Women Affected by Osteoporosis: A Real-Life Study

Version 1 : Received: 20 December 2020 / Approved: 21 December 2020 / Online: 21 December 2020 (10:42:15 CET)

How to cite: Marocco, C.; Zimatore, G.; Mocini, E.; Fornari, R.; Iolascon, G.; Gallotta, M.C.; Bimonte, V.M.; Baldari, C.; Lenzi, A.; Migliaccio, S. Effectiveness of Denosumab Therapy after Treatment with Bisphosphonates in Women Affected by Osteoporosis: A Real-Life Study. Preprints 2020, 2020120498 (doi: 10.20944/preprints202012.0498.v1). Marocco, C.; Zimatore, G.; Mocini, E.; Fornari, R.; Iolascon, G.; Gallotta, M.C.; Bimonte, V.M.; Baldari, C.; Lenzi, A.; Migliaccio, S. Effectiveness of Denosumab Therapy after Treatment with Bisphosphonates in Women Affected by Osteoporosis: A Real-Life Study. Preprints 2020, 2020120498 (doi: 10.20944/preprints202012.0498.v1).

Abstract

Denosumab is a human monoclonal antibody that neutralizes RANKL, a cytokine able to interact with the RANK receptor on preosteoclasts and osteoclasts, decreasing their recruitment and differentiation, leading to a decreased bone resorption. The aim of this observational real-life study was to analyze adherence to denosumab therapy, its effectiveness in increasing bone mineral density (BMD) and in modulating biochemical skeletal markers upon previous treatments with bisphosphonates in a group of post-menopausal women affected by osteoporosis. Women were recruited in the specialized center from March 2012 to September 2019. Biochemical markers were recorded at baseline and every six months prior to subsequent drug injection. Dual X-ray Absorptiometry was requested at baseline and after 18/24 months. Comparing BMD at baseline and after denosumab therapy in naive patients and in those previously treated with bisphosphonates, a positive therapeutic effect was observed in both groups. The results of our real-life study demonstrate, as expected, that BMD values significantly increased upon denosumab treatment. Interestingly, denosumab showed an increased effectiveness in patients previously treated with bisphosphonates. Moreover, biochemical markers data indicate that osteoporotic patients, without other concomitant unstable health conditions, could be evaluated once a year, decreasing the number of specialistic center access.

Subject Areas

Osteoporosis; anti-resorptive drugs; therapeutic adherence; bone mineral density; biochemical markers

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.